Span Divergent Ltd
₹ 29.9
-3.77%
24 Aug
- close price
About
Incorporated in 1972, Span Divergent Ltd deals in different businesses through various subsidiaries.[1]
Key Points
- Market Cap ₹ 21.7 Cr.
- Current Price ₹ 29.9
- High / Low ₹ 51.5 / 20.9
- Stock P/E
- Book Value ₹ 20.5
- Dividend Yield 0.00 %
- ROCE -30.0 %
- ROE -41.5 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 45.0 to 32.6 days.
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last 3 years: -15.9%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 75.47 | 0.00 | 2.87 | 14.57 | 24.14 | 9.38 | 7.40 | 13.09 | 12.52 | 12.33 | 8.96 | 17.23 | 17.18 | |
| 74.28 | 5.23 | 8.37 | 25.16 | 31.34 | 15.16 | 9.64 | 12.67 | 11.42 | 10.94 | 9.61 | 19.82 | 20.16 | |
| Operating Profit | 1.19 | -5.23 | -5.50 | -10.59 | -7.20 | -5.78 | -2.24 | 0.42 | 1.10 | 1.39 | -0.65 | -2.59 | -2.98 |
| OPM % | 1.58% | -191.64% | -72.68% | -29.83% | -61.62% | -30.27% | 3.21% | 8.79% | 11.27% | -7.25% | -15.03% | -17.35% | |
| 53.94 | 9.98 | 4.04 | 2.57 | -0.76 | 1.96 | 0.82 | -7.54 | -3.45 | 1.77 | 1.25 | 1.29 | 0.99 | |
| Interest | 4.39 | 0.03 | 0.20 | 1.70 | 1.89 | 1.99 | 1.58 | 1.08 | 1.00 | 0.72 | 0.60 | 0.43 | 0.49 |
| Depreciation | 5.96 | 0.18 | 0.82 | 2.60 | 3.62 | 3.45 | 3.11 | 2.17 | 2.17 | 1.64 | 1.09 | 1.17 | 1.09 |
| Profit before tax | 44.78 | 4.54 | -2.48 | -12.32 | -13.47 | -9.26 | -6.11 | -10.37 | -5.52 | 0.80 | -1.09 | -2.90 | -3.57 |
| Tax % | 12.93% | 27.97% | 5.24% | 1.46% | 4.31% | -7.02% | 0.82% | -2.12% | -1.81% | 2.50% | 17.43% | 1.38% | |
| 38.99 | 3.28 | -2.61 | -12.50 | -14.05 | -8.61 | -6.16 | -10.15 | -5.42 | 0.79 | -1.28 | -2.95 | -3.62 | |
| EPS in Rs | 53.59 | 6.06 | -4.78 | -22.89 | -22.28 | -14.23 | -10.23 | -17.94 | -9.25 | 1.79 | -1.68 | -3.44 | -4.79 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 11% |
| TTM: | 172% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 9% |
| 3 Years: | -38% |
| TTM: | -187% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -7% |
| 5 Years: | 16% |
| 3 Years: | 43% |
| 1 Year: | 36% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -41% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.28 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 7.26 |
| Reserves | 54.41 | 44.71 | 43.11 | 30.61 | 19.87 | 12.12 | 6.56 | -3.24 | -8.30 | -7.35 | -8.27 | 7.60 |
| 0.34 | 0.19 | 13.12 | 23.18 | 22.30 | 19.19 | 17.99 | 13.19 | 11.15 | 9.11 | 8.36 | 7.14 | |
| 3.80 | 0.44 | 2.97 | 4.02 | 1.64 | 2.56 | 4.27 | 12.27 | 17.02 | 16.64 | 17.28 | 6.90 | |
| Total Liabilities | 65.83 | 50.80 | 64.66 | 63.27 | 49.27 | 39.33 | 34.28 | 27.68 | 25.33 | 23.86 | 22.83 | 28.90 |
| 2.20 | 2.15 | 8.15 | 25.91 | 22.47 | 20.19 | 17.72 | 15.36 | 13.12 | 10.75 | 9.64 | 9.33 | |
| CWIP | 0.09 | 0.06 | 10.95 | 0.00 | 0.06 | 0.13 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 45.81 | 35.55 | 27.87 | 25.50 | 16.36 | 10.07 | 9.43 | 4.03 | 3.95 | 4.69 | 6.30 | 5.15 |
| 17.73 | 13.04 | 17.69 | 11.86 | 10.38 | 8.94 | 7.11 | 8.29 | 8.26 | 8.42 | 6.89 | 14.42 | |
| Total Assets | 65.83 | 50.80 | 64.66 | 63.27 | 49.27 | 39.33 | 34.28 | 27.68 | 25.33 | 23.86 | 22.83 | 28.90 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60.91 | -7.36 | -5.38 | -11.74 | -7.09 | -0.12 | -0.21 | 7.03 | 1.98 | 2.50 | 1.86 | 0.22 | |
| -12.13 | 13.39 | -5.55 | 0.81 | 10.05 | 5.89 | 1.99 | -2.05 | 0.53 | 0.12 | -1.05 | 1.55 | |
| -42.19 | -12.17 | 12.74 | 7.37 | -2.82 | -7.32 | -1.41 | -5.50 | -2.30 | -2.09 | -1.15 | 4.12 | |
| Net Cash Flow | 6.59 | -6.13 | 1.80 | -3.57 | 0.14 | -1.55 | 0.37 | -0.52 | 0.20 | 0.53 | -0.34 | 5.89 |
| Free Cash Flow | 47.54 | 3.91 | -21.44 | -15.13 | -6.93 | -1.46 | 1.79 | 8.12 | 1.85 | 2.12 | 1.91 | -0.19 |
| CFO/OP | 5,865% | 102% | 13% | 60% | 97% | -0% | 3% | 1,717% | 185% | 183% | -185% | -15% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 3.72 | 1.27 | 59.62 | 22.08 | 39.30 | 73.49 | 44.06 | 55.39 | 45.88 | 56.62 | 32.62 | |
| Inventory Days | 2.68 | 314.18 | 101.31 | 52.17 | 83.88 | 143.23 | 179.48 | 317.65 | 206.08 | 123.31 | 40.32 | |
| Days Payable | 1.17 | 78.54 | 39.95 | 12.44 | 79.35 | 298.01 | 213.76 | 526.78 | 480.26 | 426.66 | 136.20 | |
| Cash Conversion Cycle | 5.24 | 236.90 | 120.98 | 61.81 | 43.84 | -81.29 | 9.77 | -153.74 | -228.30 | -246.72 | -63.26 | |
| Working Capital Days | -7.01 | -705.84 | -228.22 | -185.98 | -310.52 | -400.02 | -428.58 | -599.98 | -608.63 | -930.83 | -111.43 | |
| ROCE % | -4.35% | -5.73% | -8.98% | -19.95% | -19.10% | -19.87% | -15.86% | -3.67% | -9.50% | 36.03% | -186.79% | -29.96% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of employees (parent company) employees ・Standalone data |
|
|||||||||
| Cashew Processing business revenue (Dryfruit Factory LLP) Rs. Lakhs |
||||||||||
| Tissue Culture business revenue (Aranya Agri Biotech LLP) Rs. Lakhs |
||||||||||
| Trading business revenue (Biospan Scientific LLP + Biospan Contamination Control Solutions) Rs. Lakhs |
||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication
- Span Divergent Limited-Financial Results For The Quarter End June 30, 2026
-
Board Meeting Outcome for Span Divergent Limited Outcome Of Board Meeting Held On August 11, 2026
- Board approved Q1 FY27 unaudited standalone and consolidated results on August 11, 2026.
-
Board Meeting Intimation for Span Divergent Limited Board Meeting To Be Held On August 11, 2026
- Board to consider Q1 FY27 unaudited standalone and consolidated results on August 11, 2026; trading window closed.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- RTA confirmed timely processing of dematerialization requests for quarter ended June 30, 2026.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Business Overview:[1][2]
SDL operates across multiple business segments through dedicated subsidiaries in the Food, Agriculture, and Life Sciences verticals. It also provides management consulting and support services, offering financial, technical, and operational expertise to its group entities. The company actively oversees compliance, networking, and business development activities, while closely monitoring subsidiary performance and implementing strategic guidance and corrective measures as approved by the Board.